Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide;Therapie intraokulärer, ödematöser, proliferativer und neovaskulärer erkrankungen durch intravitreales triamcinolon-acetonid

Klinische Monatsblatter fur Augenheilkunde

Volumn 220, Issue 6, 2003, Pages 384-390

  Jonas, Jost B ^a   Kreissig, Ingrid ^a   Degenring, Robert F ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Age related macular degeneration; Anti angiogenesis; Diabetic macular oedema; Iris neovascularisation; Triamcinolone acetonide

Indexed keywords

TRIAMCINOLONE ACETONIDE;

AQUEOUS HUMOR; CATARACT EXTRACTION; CELL PROLIFERATION; DIABETES MELLITUS; DRUG EFFECT; EYE DISEASE; FILTERING OPERATION; HUMAN; NEOVASCULARIZATION (PATHOLOGY); RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; REVIEW; VISUAL ACUITY; VITREORETINOPATHY;

EID: 0038444758     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40272     Document Type: Review

References (69)

1. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001; 108: 765-772
2. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993; 231: 34-40
3. Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudric A. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 2003; 135: 246-249
4. Benitez Del Castillo Sanchez JM, Garcia Sanchez J. Intravitreal injection of triamcinolone acetonide in non infectious uveitis. Arch Soc Esp Oftalmol 2001; 76: 661-664
5. Benz MS, Murray TG, Dubovy SR, Katz RS, Eifrig CW. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 2003; 121: 271-273
6. Berger AS, Cheng CK, Pearson PA, Ashton P, Crooks PA, Cynkowski T et al. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1996; 37: 2318-2325
7. Bui Quoc E, Bodaghi B, Adam R, Burtin T, Cassoux N, Dreifuss S, Fardeau C, Lehoang P. Intraocular pressure elevation after subtenon injection of triamcinolone acetonide during uveitis. J Fr Ophtalmol 2002; 25: 1048-1056
8. Bynoe LA, Weiss JN. Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults. Am J Ophthalmol 2003; 135: 382-384
9. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow-up. Aust N Z J Ophthalmol 1998; 26: 277-281
10. Chen EP, Steinhorst UH, Samsa GP, Saloupis PT, Hatchell DL. The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1992; 33: 2160-2164
11. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001; 119: 399-404
12. Coats ML, Peyman GA. Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina 1992; 12: 46-51
13. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003; 29: 27-33
14. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996; 103: 2099-2104
15. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-250
16. Degenring RF, Jonas JB. Intravitreal injection of triamcinolone acetonide as treatment of chronic uveitis. Br J Ophthalmol 2003; 87: 361
17. Degenring RF, Kamppeter B, Kreissig I, Jonas JB. Morphologic and functional changes after intravitreal triamcinolone acetonide for retinal vein occlusion. Acta Ophthalmol, 2003; im Druck
18. Ghopal L, Bhende M, Sharma T. Vitrectomy for accidental intraocula steroid injection. Retina 1995; 15: 295-299
19. Graham RO, Peyman GA. Intravitreal injection of dexamethasone Treatment of experimentally induced endophthalmitis. Arch Ophthal mol 1974; 92: 149-154
20. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retina vein occlusion. Br J Ophthalmol 2002; 86: 247-248
21. Hefferman JT, Futterman S, Kalina RE. Dexamethasone inhibition of experimental endothelial cell proliferation in retinal venules. Invest Ophthalmol Vis Sci 1978; 17: 565-568
22. Ip MS, Kumar KS. Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol 2002; 120: 1217-1219
23. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985; 103: 708-711
24. Jaffe GJ, Ben-nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 107: 2024-2033
25. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000; 84: 1064-1067
26. Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131: 468-471
27. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Short Communication. Graefe's Arch Clin Exp Ophthalmol 2001; 239: 464-465
28. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132: 425-427
29. Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 2001; 10: 284-287
30. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Graefe's Arch Clin Exp Ophthalmol 2001; 239: 464-465
31. Jonas JB, Degenring RF. Intravitreale Injektion von kristallinem Triamcinolon Acetonid als Therapie des diffusen diabetischen Makulaödems. Klin Monatsbl Augenheilkd 2002; 219: 429-432
32. Jonas JB. Concentration of intravitreally applicated triamcinolone acetonide in aqueous humour. Brief Report Br J Ophthalmol 2002; 86: 1066
33. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefe's Arch Clin Exp Ophthalmol 2002; 240: 782-783
34. Jonas JB, Kreissig I, Degenring RF. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative agerelated macular degeneration. Brief Report. Graefe's Arch Clin Exp Ophthalmol 2002; 240: 872-873
35. Jonas JB. Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil. Br J Ophthalmol 2002; 86: 1450-1451
36. Jonas JB, Söfker A. Intravitreal triamcinolone acetonide for cataract surgery with iris neovascularisation. J Cataract Refr Surg 2002; 28: 2040-2041
37. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87: 24-27
38. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone acetonide for diabetic macular edema. Arch Ophthalmol 2003; 121: 57-61
39. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 2003; 87: 462-468
40. Jonas JB, Kreissig I, Degenring RF. Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol 2003; 121: 729-730
41. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Arch Ophthalmol, 2003; im Druck
42. Jonas JB, Söfker A, Degenring RF. Intravitreal triamcinolone acetonide as additional tool in pars plana vitrectomy for proliferate diabetic retinopathy. Eur J Ophthalmol, 2003; im Druck
43. Jonas JB, Kreissig I, Degenring RF. Repeated intravitreal triamcinolone injections as treatment of ischemic ophthalmopathy. Eur J Ophthalmol, 2003; im Druck
44. Jonas JB, Söfker A, Hayler J, Degenring RF. Intravitreal crystalline triamcinolone acetonide as additional tool in pars plana vitrectomy for complicated proliferative vitreoretinopathy? Acta Ophthalmol, zur Publikation angenommen
45. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979; 77: 171-180
46. Machemer R. Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye. Retina 1996; 16: 166-167
47. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 2001; 119: 1380-1383
48. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafitto CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-927
49. McCuen BW 2d, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981; 91: 785-788
50. Gillies MC, Luo W, Chua W, Cherepanoff S, Billson FA, Mitchell P, Simpson J. The efficacy of a single intravitreal injection of triamcinolone for neovascular age-related macular degeneration. One year results of a randomised clinical trial: IVTAS. Invest Ophthalmol Vis Sci 2001; 42, Suppl: ARVO. Abstract # 2808
51. Modarres M, Parvaresh MM, Peyman GA. Accidental subretinal injection of triamcinolone acetonide. Ophthalmic Surg Lasers 1998; 29: 935-938
52. Moshfeghi DM, Lowder CY, Roth DB, Kaiser PK. Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol 2002; 134: 132-134
53. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust NZ J Ophthalmol 1995; 23: 293-298
54. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHCI1 in exudative age-related macular degeneration. Clin Experiment Ophthalmol 2001; 29: 188-192
55. Penfold PL, Wen L, Madigan MC, King NJ, Provis JM. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002; 43: 3125-3130
56. Penfold PL. Intravitreal triamcinolone in recurrence of choroidal neovascularisation. Br J Ophthalmol 2002; 86: 600-601
57. Penn JS, Rajaramam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001; 42: 283-290
58. Peyman GA, Cheema R, Conway MD, Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 2000; 20: 554-555
59. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002; 86: 527-529
60. Reinhard T, Sundmacher R. Adjunctive intracameral application of corticosteroids in patients with endothelial immune reactions after penetrating keratoplasty. A pilot study. Transplant International. I Transpl Int 2002; 15: 81-88
61. Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, Ishibashi T. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002; 240: 423-429
62. Schindler RH, Chandler DB, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982; 93: 415-417
63. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985; 103: 1567-1569
64. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980; 90: 810-816
65. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferation with intravitreal corticosteroid. Am J Ophthalmol 1980; 89: 131-136
66. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefe's Arch Clin Exp Ophthalmol 2002; 240: 42-48
67. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 1155-1159
68. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999; 27: 431-432
69. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001; 29: 2-6